Disclosure Plus

Bonne Co., Ltd. Allegations of Embezzlement and Breach of Trust Involving 100 Million Won

Shin Ha-yeon
2026-08-18 16:21:39
[Edaily Reporter Shin Ha-yeon ] Bonne Co., Ltd.(226340)announced on the 18th that allegations of embezzlement and breach of trust have been raised against its former and current CEOs.

The amount in question is 102.86 million won, which represents 0.3% of the company’s equity capital of 38.28308 billion won. The allegations were confirmed through an investigation by an external expert appointed by the audit committee following an internal tip-off, as well as through forensic procedures.

The executives involved are former CEO Mr. Lim and current CEO Mr. Kang. The company’s board of directors has decided to recover the full amount confirmed to date and plans to proceed with recovery after completing necessary procedures, including consultations with the parties involved.

In addition, Hyosung plans to strengthen the independence and effectiveness of its audit functions and implement measures to improve internal controls, such as operating a Transparency Management Committee and strengthening prior approval procedures.

The company stated, “The amount in question is based on what has been confirmed so far and may change depending on the auditor’s future audit and review procedures, as well as investigations and determinations by relevant authorities,” adding, “We plan to issue another disclosure if any additional details are confirmed or finalized.”

Economy

Corporation

IT·Science

Economy

Jay Y. Lee Visits His Father’s Grave Immediately After Returning from the UAE… Commemorating the 6th Anniversary of Lee Kun-Hee’s Passing

On the sixth anniversary of the passing of the late Lee Kun-Hee, former chairman of SamsungElectronics, Jay Y. Lee and executives from major affiliate companies gathered at the family cemetery in Suwo…
2026-10-23 10:34:32

Corporation

Is the Efficacy Announcement a “Predetermined Outcome”?… “Some Indicators Point in the Desired Direction”

Aptabio Therapeutics Inc.(293780)has expressed confidence ahead of the announcement of the efficacy of its kidney disease treatment candidate “Isuzinaxib” (APX-115). This follows the company’s selecti…
2026-10-23 12:02:02

IT·Science

Orum Therapeutics, Inc. Welcomes U.S. BD Expert Back to Board… A Breakthrough After BMS?

#Orum Therapeutics, Inc. has reappointed a U.S. business development (BD) expert to its board of directors and expanded the limit on stock options granted to U.S. employees. At an investor briefing he…
2026-10-23 11:29:02